FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311508919> ?p ?o ?g. }

• W4311508919 abstract "VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome has recently been described as an autoinflammatory disease associated with severe adult-onset inflammatory manifestations. The various clinical manifestations include recurrent high-grade fever, neutrophilic dermatoses, cutaneous vasculitis, chondritis of the ear and nose, pulmonary infiltrates, cytopenia, uveitis, gastrointestinal pain or inflammation, aortitis, hepatosplenomegaly, and hematological disorders. VEXAS syndrome is caused by somatic mutations of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene in myeloid-lineage cells. It is characterized by vacuolated myeloid and erythroid progenitor cells seen by bone marrow biopsy. We report the case of a 64-year-old Japanese man with VEXAS syndrome. At age 63, he was referred to us with a recurrent erythema on the hands associated with a general fever of 38-40°C that had persisted for 4 or 5 days and had recurred about once a month for a year. The skin rash appeared 2 or 3 days after the onset of each fever episode. Computed tomography (CT) of the chest revealed bilateral hilar lymphadenopathy (BHL), and the mediastinal lymph nodes were swollen. Sarcoidosis was suspected but was ruled out by several tests. Laboratory examinations showed elevated inflammatory markers. Bone marrow examination showed the vacuolization of myeloid precursor cells. A skin biopsy revealed dense dermal, predominantly perivascular, infiltrates. These consisted of mature neutrophils admixed with myeloperoxidase-positive CD163-positive myeloid cells, lymphoid cells and eosinophils. Sequencing analysis identified the somatic UBA1 variant c.122T > C, which results in p.Met41Thr. Treatment with oral prednisone (15 mg/day) and monthly intravenous tocilizumab injections (400 mg) completely resolved the symptoms. Neutrophils are a major source of reactive oxygen species, and the present case demonstrated numerous neutrophilic infiltrates. We hypothesize that the patient might have had elevated derivatives of reactive oxygen metabolites (d-ROMs). d-ROM quantification is a simple method for detecting hydroperoxide levels, and clinical trials have proven it useful for evaluating oxidative stress. In this study, we measured serum d-ROM before and after oral prednisone and tocilizumab treatment. The levels decreased significantly during treatment." @default.
• W4311508919 created "2022-12-26" @default.
• W4311508919 creator A5005243857 @default.
• W4311508919 creator A5005286789 @default.
• W4311508919 creator A5007231716 @default.
• W4311508919 creator A5015620812 @default.
• W4311508919 creator A5035273536 @default.
• W4311508919 creator A5037417355 @default.
• W4311508919 creator A5039176890 @default.
• W4311508919 creator A5043316836 @default.
• W4311508919 creator A5049681881 @default.
• W4311508919 creator A5050977501 @default.
• W4311508919 creator A5051569845 @default.
• W4311508919 creator A5056472214 @default.
• W4311508919 creator A5064949815 @default.
• W4311508919 creator A5072187903 @default.
• W4311508919 creator A5081250273 @default.
• W4311508919 creator A5085073972 @default.
• W4311508919 creator A5090534485 @default.
• W4311508919 date "2022-12-05" @default.
• W4311508919 modified "2023-10-17" @default.
• W4311508919 title "A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment" @default.
• W4311508919 cites W2019221616 @default.
• W4311508919 cites W2405556538 @default.
• W4311508919 cites W3094287941 @default.
• W4311508919 cites W3131395638 @default.
• W4311508919 cites W3157784839 @default.
• W4311508919 cites W3177305227 @default.
• W4311508919 cites W3195291942 @default.
• W4311508919 cites W3197876120 @default.
• W4311508919 cites W3200185753 @default.
• W4311508919 cites W3206162992 @default.
• W4311508919 cites W4200134430 @default.
• W4311508919 cites W4210324632 @default.
• W4311508919 cites W4213271132 @default.
• W4311508919 cites W4213428281 @default.
• W4311508919 cites W4220849870 @default.
• W4311508919 cites W4223538031 @default.
• W4311508919 cites W4282829870 @default.
• W4311508919 cites W4285009361 @default.
• W4311508919 doi "https://doi.org/10.3389/fmed.2022.1046820" @default.
• W4311508919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36544501" @default.
• W4311508919 hasPublicationYear "2022" @default.
• W4311508919 type Work @default.
• W4311508919 citedByCount "2" @default.
• W4311508919 countsByYear W43115089192023 @default.
• W4311508919 crossrefType "journal-article" @default.
• W4311508919 hasAuthorship W4311508919A5005243857 @default.
• W4311508919 hasAuthorship W4311508919A5005286789 @default.
• W4311508919 hasAuthorship W4311508919A5007231716 @default.
• W4311508919 hasAuthorship W4311508919A5015620812 @default.
• W4311508919 hasAuthorship W4311508919A5035273536 @default.
• W4311508919 hasAuthorship W4311508919A5037417355 @default.
• W4311508919 hasAuthorship W4311508919A5039176890 @default.
• W4311508919 hasAuthorship W4311508919A5043316836 @default.
• W4311508919 hasAuthorship W4311508919A5049681881 @default.
• W4311508919 hasAuthorship W4311508919A5050977501 @default.
• W4311508919 hasAuthorship W4311508919A5051569845 @default.
• W4311508919 hasAuthorship W4311508919A5056472214 @default.
• W4311508919 hasAuthorship W4311508919A5064949815 @default.
• W4311508919 hasAuthorship W4311508919A5072187903 @default.
• W4311508919 hasAuthorship W4311508919A5081250273 @default.
• W4311508919 hasAuthorship W4311508919A5085073972 @default.
• W4311508919 hasAuthorship W4311508919A5090534485 @default.
• W4311508919 hasBestOaLocation W43115089191 @default.
• W4311508919 hasConcept C142724271 @default.
• W4311508919 hasConcept C203014093 @default.
• W4311508919 hasConcept C2775934546 @default.
• W4311508919 hasConcept C2779134260 @default.
• W4311508919 hasConcept C2779282312 @default.
• W4311508919 hasConcept C2779440204 @default.
• W4311508919 hasConcept C2780007613 @default.
• W4311508919 hasConcept C2780366003 @default.
• W4311508919 hasConcept C2780439664 @default.
• W4311508919 hasConcept C71924100 @default.
• W4311508919 hasConceptScore W4311508919C142724271 @default.
• W4311508919 hasConceptScore W4311508919C203014093 @default.
• W4311508919 hasConceptScore W4311508919C2775934546 @default.
• W4311508919 hasConceptScore W4311508919C2779134260 @default.
• W4311508919 hasConceptScore W4311508919C2779282312 @default.
• W4311508919 hasConceptScore W4311508919C2779440204 @default.
• W4311508919 hasConceptScore W4311508919C2780007613 @default.
• W4311508919 hasConceptScore W4311508919C2780366003 @default.
• W4311508919 hasConceptScore W4311508919C2780439664 @default.
• W4311508919 hasConceptScore W4311508919C71924100 @default.
• W4311508919 hasLocation W43115089191 @default.
• W4311508919 hasLocation W43115089192 @default.
• W4311508919 hasLocation W43115089193 @default.
• W4311508919 hasLocation W43115089194 @default.
• W4311508919 hasOpenAccess W4311508919 @default.
• W4311508919 hasPrimaryLocation W43115089191 @default.
• W4311508919 hasRelatedWork W196940514 @default.
• W4311508919 hasRelatedWork W1999841167 @default.
• W4311508919 hasRelatedWork W2020979289 @default.
• W4311508919 hasRelatedWork W2049462083 @default.
• W4311508919 hasRelatedWork W2150582250 @default.
• W4311508919 hasRelatedWork W2228386951 @default.
• W4311508919 hasRelatedWork W2341977336 @default.
• W4311508919 hasRelatedWork W2427457889 @default.
• W4311508919 hasRelatedWork W3209599045 @default.

• next